BioSpace News Archive

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company has acquired an exclusive license from Alexion Pharmaceuticals

Novamind included as fast entry addition to the North American Psychedelics Index, the underlying index of the Horizons Psychedelic Stock Index ETF

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the SVB Leerink 10th Annual Global Healthcare Conference.

Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, today announced that management will present and speak on the RF filter industry panel at the Arete Tech Conference taking place March 3-4, 2021.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, and Farmacore Biotechnology today announced that Blanver Farmoquímica e Farmacêutica S.A. has joined their consortium to develop and commercialize a novel COVID-19 vaccine in Latin America.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) (the Company), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a definitive agreement with a single healthcare-focused institutional investor in a private placement of 8,888,890 common shares and warrants to purchase 6,666,668 common shares

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company developing product candidates for Alzheimer’s disease, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for simufilam, its lead drug candidate for the treatment of Alzheimer’s disease.

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has received the official Type A meeting minutes from the U.S. Food and Drug Administration (“FDA”) Division of Neurology II (the “Division”) regarding the requirements for resubmission of the Qtrypta™

Dialyze Direct is pleased to announce the appointment of Stuart Paul as Chief Commercial Officer.

Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2021 Animal Health Summit Virtual Forum on Thursday, Feb. 25, 2021. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 7:50 a.m. ET.